DOCSLIB.ORG

Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis Article Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis Oliver W. Gramlich1,2,AlexanderJ.Brown3,4, Cheyanne R. Godwin1,2, Michael S. Chimenti5, Lauren K. Boland6, James A. Ankrum6, and Randy H. Kardon1,2 1 Department of Ophthalmology and Visual Sciences, The University of Iowa, Iowa City, IA, USA 2 Center for the Prevention and Treatment of Visual Loss, Iowa City VA Health Care System, Iowa City, IA, USA 3 Department of Biomedical Research, National Jewish Health, Denver, CO, USA 4 Department of Immunology & Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 5 Iowa Institute of Human Genetics, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA 6 Roy J. Carver Department of Biomedical Engineering College, The University of Iowa, Iowa City, IA, USA Correspondence: Oliver W. Purpose: The purpose of this study was to determine mesenchymal stem cell (MSC) Gramlich, Department of therapy efficacy on rescuing the visual system in the experimental autoimmune Ophthalmology and Visual Sciences, encephalomyelitis (EAE) model of multiple sclerosis (MS) and to provide new mecha- The University of Iowa, 200 Hawkins nistic insights. Dr, Iowa City, IA 52242, USA. e-mail: Methods: [email protected] EAE was induced in female C57BL6 mice by immunization with myelin oligo- dendrocyte glycoprotein (MOG)35–55, complete Freund’s adjuvant, and pertussis toxin. Received: March 23, 2020 The findings were compared to sham-immunized mice. Half of the EAE mice received Accepted: May 26, 2020 intraperitoneally delivered stem cells (EAE + MSC). Clinical progression was monitored Published: July 10, 2020 according to a five-point EAE scoring scheme. Pattern electroretinogram (PERG) and Keywords: optic neuritis; EAE; retinal nerve fiber layer (RNFL) thickness were measured 32 days after induction. Retinas mesenchymal stem cells; were harvested to determine retinal ganglion cell (RGC) density and prepared for RNA- pattern-ERG; retinal ganglion cells sequencing. Citation: GramlichOW,BrownAJ, Results: EAE animals that received MSC treatment seven days after EAE induction Godwin CR, Chimenti MS, Boland LK, showed significantly lower motor-sensory impairment, improvement in the PERG ampli- Ankrum JA, Kardon RH. Systemic tude, and preserved RNFL. Analysis of RNA-sequencing data demonstrated statistically mesenchymal stem cell treatment significant differences in gene expression in the retina of MSC-treated EAE mice. Differ- mitigates structural and functional entially expressed genes were enriched for pathways involved in endoplasmic reticulum retinal ganglion cell degeneration in stress, endothelial cell differentiation, HIF-1 signaling, and cholesterol transport inthe a mouse model of multiple sclerosis. MSC-treated EAE group. Trans Vis Sci Tech. 2020;9(8):16, Conclusions: https://doi.org/10.1167/tvst.9.8.16 Systemic MSC treatment positively affects RGC function and survival in EAE mice. Better cholesterol handling by increased expression of Abca1, the cholesterol efflux regulatory protein, paired with the resolution of HIF-1 signaling activation might explain the improvements seen in PERG of EAE animals after MSC treatment. Translational Relevance: Using MSC therapy in a mouse model of MS, we discovered previously unappreciated biochemical pathways associated with RGC neuroprotection, which have the potential to be pharmacologically targeted as a new treatment regimen. cells, which causes visual impairment, fatigue, motor Introduction disabilities, pain, and cognitive deficits. Approximately 2.5 million people, primarily young adults, are afflicted Multiple sclerosis (MS) is a chronic neurodegen- with MS. The average age at disease onset is 30 years, erative disease, primarily mediated by autoreactive T and half of the patients require a wheelchair within Copyright 2020 The Authors tvst.arvojournals.org | ISSN: 2164-2591 1 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. Downloaded from tvst.arvojournals.org on 09/24/2021 Mesenchymal Stem Cell Therapy in Experimental Optic Neuritis TVST | July 2020 | Vol. 9 | No. 8 | Article 16 | 2 1–3 25 years of diagnosis. Vision loss due to acute optic dendrocyte glycoprotein (MOG)35–55 induced experi- neuritis and subsequent retinal ganglion cell (RGC) mental autoimmune encephalomyelitis (EAE) model. loss is the major initial feature in approximately 20 We sought to provide data showing that systemic MSC to 45% of cases with MS.4 There is a very high treatment significantly reduces motor-sensory impair- likelihood that patients diagnosed with MS by other ment in EAE mice. Furthermore, we used pattern initial symptoms will have at least one episode of MS- electroretinography (PERG) recordings to indicate related optic neuritis in the future. Many patients with rescue of the PERG amplitude in MSC-treated mice, acute optic neuritis completely recover their vision, and measurement of RNFL to indicate preservation but approximately 40% suffer from permanent vision of axons. Bioinformatics of the retina, including optic loss. Notably, faster recovery of vision is correlated nerve tissue, was used to characterize gene expres- with onset of treatment and the earlier the treatment sion to discover processes related to RGC death (e.g. starts, the better the prognosis is for visual outcome.5,6 HIF-1 pathway activation and endoplasmic reticu- Patients with MS with no history of optic neuritis show lum [ER] unfolded protein response), in MSC-treated evidence of RGC loss and thinning of the retinal nerve EAE mice when compared to untreated EAE mice. fiber layer (RNFL), determined by optical coherence Moreover, we identified differentially regulated gene tomography (OCT) imaging.7 Furthermore, impaired clusters associated with endothelial cell differentiation, contrast sensitivity in patients with MS correlates with visual system development, and response to retinoic severity of central nervous system (CNS) lesion size,8,9 acid that also influence regulation of cholesterol trans- demonstrating that the visual pathway is an important port in EAE mice having received systemic MSC treat- indicator of disease activity, even in patients with MS ment. These data indicate that MSC treatment in EAE- who have no visual symptoms and no history of optic mediated optic neuritis involves previously unappre- neuritis. ciated pathways associated with neuroprotection and Approaches using mesenchymal stem cells (MSCs) repair of visual system impairments that may be future in animal models and clinical studies have shown targets for therapeutics. considerable promise in reducing the severity of autoimmune-mediated disorders by decreasing effector T-cell populations and promoting T-regulatory cells. Methods There are currently 11 ongoing and 13 completed clinical trials worldwide using different sources of Animals and EAE Induction MSC (bone marrow-derived, umbilical cord-derived, etc.) and multiple routes of administration for treat- All animal experiments were approved by the Iowa ments (clinicaltrials.gov). One of the first clinical safety City VAHealth Care System Institutional Animal Care studies using MSCs in patients with secondary progres- and Use Committee (IACUC) and were conducted in sive MS indicated preservation of RNFL thickness accordance with the ARVO Statement for the Use of and improvement of visual function after MSC admin- Animals in Ophthalmic and Vision Research. Female istration.10 It is known that MSC has immunomod- two month old C57BL6/J (B6) mice were purchased ulatory properties that can directly suppress T-cell from Jackson Laboratories (Bar Harbor, ME) and activation11 and likely serve to reduce CNS damage. housed on a 12-hour light-dark cycle with food ad Moreover, recent studies have shown that MSC secrete libitum. EAE was induced in 40 mice, as described a large variety of trophic factors, such as platelet- by Bittner et al.14 by immunization with 200 μl derived growth factor, hepatocyte growth factor, and solution containing 200 μgMOG35–55 (Sigma Aldrich, insulin-like growth factor to promote retinal neuro- St. Louis, MO) emulsified with complete Freund’s protection.11,12 MSCs are also considered capable of adjuvant (Sigma) containing 2 mg/mL mycobacterium triggering remyelination,13 but mechanisms are not tuberculosis (BD Difco, Franklin Lakes, NJ) subcu- well understood. Discovery of biochemical pathways taneously at two sites along the back. A group through which MSCs improve visual function and of 20 control mice received a sham immunization facilitate RGC neuroprotection after an inflamma- with an equal volume of phosphate-buffered saline tory demyelinating event could provide new thera- (PBS) instead of MOG mixed with complete Freund’s peutic targets that can be augmented more specifi- adjuvant (control [CTRL]). MOG and CTRL mice cally through small molecules, drugs, diet, or gene- were injected with 400 ng pertussis toxin in 200 μl PBS therapeutic approaches. intraperitoneally at day 0 (day of immunization) and The purpose of our study is to overcome this knowl- again on day two. Clinical progression was monitored edge gap by validating systemic MSC therapy efficiency daily according to a five-point EAE scoring system by on rescuing the visual system using the myelin oligo- the following criteria: 0 = no symptoms, 0.5 = partial Downloaded from tvst.arvojournals.org on 09/24/2021 Mesenchymal
Load more

Recommended publications
  • Snps) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/07/06/dmd.118.082164.DC1 1521-009X/46/9/1372–1381$35.00 https://doi.org/10.1124/dmd.118.082164 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:1372–1381, September 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction s Duan Liu, Sisi Qin, Balmiki Ray,1 Krishna R. Kalari, Liewei Wang, and Richard M. Weinshilboum Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota Received April 22, 2018; accepted June 28, 2018 ABSTRACT Downloaded from CYP1A1 expression can be upregulated by the ligand-activated aryl fashion. LCLs with the AA genotype displayed significantly higher hydrocarbon receptor (AHR). Based on prior observations with AHR-XRE binding and CYP1A1 mRNA expression after 3MC estrogen receptors and estrogen response elements, we tested treatment than did those with the GG genotype. Electrophoretic the hypothesis that single-nucleotide polymorphisms (SNPs) map- mobility shift assay (EMSA) showed that oligonucleotides with the ping hundreds of base pairs (bp) from xenobiotic response elements AA genotype displayed higher LCL nuclear extract binding after (XREs) might influence AHR binding and subsequent gene expres- 3MC treatment than did those with the GG genotype, and mass dmd.aspetjournals.org sion.
    [Show full text]
  • Protein Interactions in the Cancer Proteome† Cite This: Mol
    Molecular BioSystems View Article Online PAPER View Journal | View Issue Small-molecule binding sites to explore protein– protein interactions in the cancer proteome† Cite this: Mol. BioSyst., 2016, 12,3067 David Xu,ab Shadia I. Jalal,c George W. Sledge Jr.d and Samy O. Meroueh*aef The Cancer Genome Atlas (TCGA) offers an unprecedented opportunity to identify small-molecule binding sites on proteins with overexpressed mRNA levels that correlate with poor survival. Here, we analyze RNA-seq and clinical data for 10 tumor types to identify genes that are both overexpressed and correlate with patient survival. Protein products of these genes were scanned for binding sites that possess shape and physicochemical properties that can accommodate small-molecule probes or therapeutic agents (druggable). These binding sites were classified as enzyme active sites (ENZ), protein–protein interaction sites (PPI), or other sites whose function is unknown (OTH). Interestingly, the overwhelming majority of binding sites were classified as OTH. We find that ENZ, PPI, and OTH binding sites often occurred on the same structure suggesting that many of these OTH cavities can be used for allosteric modulation of Creative Commons Attribution 3.0 Unported Licence. enzyme activity or protein–protein interactions with small molecules. We discovered several ENZ (PYCR1, QPRT,andHSPA6)andPPI(CASC5, ZBTB32,andCSAD) binding sites on proteins that have been seldom explored in cancer. We also found proteins that have been extensively studied in cancer that have not been previously explored with small molecules that harbor ENZ (PKMYT1, STEAP3,andNNMT) and PPI (HNF4A, MEF2B,andCBX2) binding sites. All binding sites were classified by the signaling pathways to Received 29th March 2016, which the protein that harbors them belongs using KEGG.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • The Physiological Functions of Mammalian Endoplasmic Oxidoreductin 1: on Disulfides and More
    ANTIOXIDANTS & REDOX SIGNALING Volume 16, Number 10, 2012 FORUM REVIEW ARTICLE ª Mary Ann Liebert, Inc. DOI: 10.1089/ars.2011.4475 The Physiological Functions of Mammalian Endoplasmic Oxidoreductin 1: On Disulfides and More Thomas Ramming and Christian Appenzeller-Herzog Abstract Significance: The oxidative process of disulfide-bond formation is essential for the folding of most secretory and membrane proteins in the endoplasmic reticulum (ER). It is driven by electron relay pathways that transfer two electrons derived from the fusion of two adjacent cysteinyl side chains onto various types of chemical oxidants. The conserved, ER-resident endoplasmic oxidoreductin 1 (Ero1) sulfhydryl oxidases that reduce molecular oxygen to generate an active-site disulfide represent one of these pathways. In mammals, two family members exist, Ero1a and Ero1b. Recent Advances: The two mammalian Ero1 enzymes differ in transcriptional and post- translational regulation, tissue distribution, and catalytic turnover. A specific protein–protein interaction be- tween either isoform and protein disulfide isomerase (PDI) facilitates the propagation of disulfides from Ero1 via PDI to nascent polypeptides, and inbuilt oxidative shutdown mechanisms in Ero1a and Ero1b prevent excessive oxidation of PDI. Critical Issues: Besides disulfide-bond generation, Ero1a also regulates calcium release from the ER and the secretion of disulfide-linked oligomers through its reversible association with the chaperone ERp44. This review explores the functional repertoire and possible redundancy of mammalian Ero1 enzymes. Future Directions: Systematic analyses of different knockout mouse models will be the most promising strategy to shed new light on unique and tissue-specific roles of Ero1a and Ero1b. Moreover, in-depth characterization of the known physical interactions of Ero1 with peroxidases and PDI family members will help broaden our functional and mechanistic understanding of Ero1 enzymes.
    [Show full text]
  • Directing an Artificial Zinc Finger Protein to New Targets by Fusion to a Non-DNA Binding Domain
    Directing an artificial zinc finger protein to new targets by fusion to a non-DNA binding domain Wooi Fang (Catheryn) Lim A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy School of Biotechnology and Biomolecular Sciences Faculty of Science March 2016 Page | 0 THESIS/ DISSERTATION SHEET Page | i ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ WOOI FANG LIM Signed …………………………………………….............. 31-03-2016 Date …………………………………………….............. Page | i COPYRIGHT STATEMENT ‘I hereby grant the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all proprietary rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.
    [Show full text]
  • A Molecular Classification of Human Mesenchymal Stromal Cells Florian Rohart1, Elizabeth Mason1, Nicholas Matigian1, Rowland
    bioRxiv preprint doi: https://doi.org/10.1101/024414; this version posted August 11, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Rohart'et'al,'The'MSC'Signature' 1' 1' A Molecular Classification of Human Mesenchymal Stromal Cells 2' Florian Rohart1, Elizabeth Mason1, Nicholas Matigian1, Rowland Mosbergen1, 3' Othmar Korn1, Tyrone Chen1, Suzanne Butcher1, Jatin Patel2, Kerry Atkinson2, 4' Kiarash Khosrotehrani2,3, Nicholas M Fisk2,4, Kim-Anh Lê Cao3 and Christine A 5' Wells1,5* 6' 1 Australian Institute for Bioengineering and Nanotechnology, The University of 7' Queensland, Brisbane, QLD Australia 4072 8' 2 The University of Queensland Centre for Clinical Research, Herston, Brisbane, 9' Queensland, Australia, 4029 10' 3 The University of Queensland Diamantina Institute, Translational Research 11' Institute, Woolloongabba, Brisbane QLD Australia, 4102 12' 4 Centre for Advanced Prenatal Care, Royal Brisbane & Women’s Hospital, Herston, 13' Brisbane, Queensland, Australia, 4029 14' 5 Institute for Infection, Immunity and Inflammation, College of Medical, Veterinary & 15' Life Sciences, The University of Glasgow, Scotland, UK G12 8TA 16' *Correspondence to: Christine Wells, [email protected] 17' bioRxiv preprint doi: https://doi.org/10.1101/024414; this version posted August 11, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • Recombinant Human ERO1-Like Protein A/ERO1L (C-6His)
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-7771: Recombinant Human ERO1-Like Protein a/ERO1L (C-6His) Gene : ERO1A Gene ID : 30001 Uniprot ID : Q96HE7 Description Source: Human Cells. MW :53kD. Recombinant Human ERO1L is produced by our Mammalian expression system and the target gene encoding Glu24-His468 is expressed with a 6His tag at the C-terminus. ERO1-Like Protein a (ERO1L) is an enzyme that belongs to the EROs family. ERO1L is expressed at high level in esophagus and upper digestive tract. ERO1L is an essential oxidoreductase that oxidizes proteins in the endoplasmic reticulum to produce disulfide bonds. ERO1L acts by oxidizing directly P4HB/PDI isomerase through a direct disulfide exchange. It associates with ERP44, demonstrating that it does not oxidize all PDI related proteins and can discriminate between PDI and related proteins. Its reoxidation probably involves electron transfer to molecular oxygen via FAD. ERO1L may be responsible for a significant proportion of reactive oxygen species (ROS) in the cell. ERO1L responses to temperature stimulus, protein thiol-disulfide exchange, protein folding with or without chaperone cofactor and transport. Product Info Amount : 10 µg / 50 µg Content : Lyophilized from a 0.2 µm filtered solution of 20mM PB,150mM NaCl,pH7.4. Lyophilized protein should be stored at -20°C, though stable at room temperature for 3 weeks. Storage condition : Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at -20°C for 3 months.
    [Show full text]
  • Identification of Pathways in Liver Repair Potentially Targeted By
    International Journal of Molecular Sciences Article Identification of Pathways in Liver Repair Potentially Targeted by Secretory Proteins from Human Mesenchymal Stem Cells Sandra Winkler 1, Madlen Hempel 1, Sandra Brückner 1, Hans-Michael Tautenhahn 1, Roland Kaufmann 2 and Bruno Christ 1,* 1 Applied Molecular Hepatology Laboratory, Department of Visceral, Transplantation, Thoracic and Vascular Surgery, University Hospital of Leipzig, Liebigstraße 21, 04103 Leipzig, Germany; [email protected] (S.W.); [email protected] (M.H.); [email protected] (S.B.); [email protected] (H.-M.T.) 2 Department of General, Visceral and Vascular Surgery, Jena University Hospital, Erlanger Allee 101, 07747 Jena, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-160-903-19121; Fax: +49-341-971-13559 Academic Editor: Maurizio Muraca Received: 26 May 2016; Accepted: 29 June 2016; Published: 9 July 2016 Abstract: Background: The beneficial impact of mesenchymal stem cells (MSC) on both acute and chronic liver diseases has been confirmed, although the molecular mechanisms behind it remain elusive. We aim to identify factors secreted by undifferentiated and hepatocytic differentiated MSC in vitro in order to delineate liver repair pathways potentially targeted by MSC. Methods: Secreted factors were determined by protein arrays and related pathways identified by biomathematical analyses. Results: MSC from adipose tissue and bone marrow expressed a similar pattern of surface markers. After hepatocytic differentiation, CD54 (intercellular adhesion molecule 1, ICAM-1) increased and CD166 (activated leukocyte cell adhesion molecule, ALCAM) decreased. MSC secreted different factors before and after differentiation.
    [Show full text]
  • Anti-ERO1L Antibody (ARG42132)
    Product datasheet [email protected] ARG42132 Package: 50 μg anti-ERO1L antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes ERO1L Tested Reactivity Hu Predict Reactivity Ms, Rat, Cow, Dog, Pig Tested Application IHC-P, WB Host Goat Clonality Polyclonal Isotype IgG Target Name ERO1L Antigen Species Human Immunogen Synthetic peptide around the internal region of Human ERO1L. (C-QSDEVPDGIKSASY) (NP_055399.1) Conjugation Un-conjugated Alternate Names ERO1-like protein alpha; ERO1L; Endoplasmic oxidoreductin-1-like protein; ERO1-alpha; ERO1-L-alpha; Ero1alpha; Oxidoreductin-1-L-alpha; EC 1.8.4.-; ERO1LA; ERO1-L Application Instructions Application table Application Dilution IHC-P 5 µg/ml WB 0.1 - 0.3 µg/ml Application Note WB: Recommend incubate at RT for 1h. IHC-P: Antigen Retrieval: Steam tissue section in Citrate buffer (pH 6.0). * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control A431 Calculated Mw 54 kDa Observed Size ~ 70 kDa Properties Form Liquid Purification Ammonium sulphate precipitation followed by affinity purification with immunogen. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA. Preservative 0.02% Sodium azide Stabilizer 0.5% BSA www.arigobio.com 1/2 Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening.
    [Show full text]
  • ERO1L Antibody Cat
    ERO1L Antibody Cat. No.: 56-977 ERO1L Antibody ERO1L Antibody immunohistochemistry analysis in formalin fixed and paraffin embedded human stomach tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human This ERO1L antibody is generated from rabbits immunized with a KLH conjugated IMMUNOGEN: synthetic peptide between 350-379 amino acids from the C-terminal region of human ERO1L. TESTED APPLICATIONS: IHC-P, WB For WB starting dilution is: 1:1000 APPLICATIONS: For IHC-P starting dilution is: 1:10~50 PREDICTED MOLECULAR 54 kDa WEIGHT: September 24, 2021 1 https://www.prosci-inc.com/ero1l-antibody-56-977.html Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: ERO1L ERO1-like protein alpha, ERO1-L, ERO1-L-alpha, 184-, Endoplasmic oxidoreductin-1-like ALTERNATE NAMES: protein, Oxidoreductin-1-L-alpha, ERO1L ACCESSION NO.: Q96HE7 PROTEIN GI NO.: 50400608 GENE ID: 30001 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References Essential oxidoreductase that oxidizes proteins in the endoplasmic reticulum to produce disulfide bonds. Acts by oxidizing directly P4HB/PDI isomerase through a direct disulfide exchange.
    [Show full text]
  • ID AKI Vs Control Fold Change P Value Symbol Entrez Gene Name *In
    ID AKI vs control P value Symbol Entrez Gene Name *In case of multiple probesets per gene, one with the highest fold change was selected. Fold Change 208083_s_at 7.88 0.000932 ITGB6 integrin, beta 6 202376_at 6.12 0.000518 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 1553575_at 5.62 0.0033 MT-ND6 NADH dehydrogenase, subunit 6 (complex I) 212768_s_at 5.50 0.000896 OLFM4 olfactomedin 4 206157_at 5.26 0.00177 PTX3 pentraxin 3, long 212531_at 4.26 0.00405 LCN2 lipocalin 2 215646_s_at 4.13 0.00408 VCAN versican 202018_s_at 4.12 0.0318 LTF lactotransferrin 203021_at 4.05 0.0129 SLPI secretory leukocyte peptidase inhibitor 222486_s_at 4.03 0.000329 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 1552439_s_at 3.82 0.000714 MEGF11 multiple EGF-like-domains 11 210602_s_at 3.74 0.000408 CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 229947_at 3.62 0.00843 PI15 peptidase inhibitor 15 204006_s_at 3.39 0.00241 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 202238_s_at 3.29 0.00492 NNMT nicotinamide N-methyltransferase 202917_s_at 3.20 0.00369 S100A8 S100 calcium binding protein A8 215223_s_at 3.17 0.000516 SOD2 superoxide dismutase 2, mitochondrial 204627_s_at 3.04 0.00619 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 223217_s_at 2.99 0.00397 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 231067_s_at 2.97 0.00681 AKAP12 A kinase (PRKA) anchor protein 12 224917_at 2.94 0.00256 VMP1/ mir-21likely ortholog
    [Show full text]
  • Krüppel-Like Factor 17 Upregulates Uterine Corin Expression and Promotes Spiral Artery Remodeling in Pregnancy
    Krüppel-like factor 17 upregulates uterine corin expression and promotes spiral artery remodeling in pregnancy Can Wanga, Zhiting Wanga, Meiling Hea, Tiantian Zhoua, Yayan Niua,b, Shengxuan Sunc, Hui Lia, Ce Zhanga, Shengnan Zhanga, Meng Liua, Ying Xud, Ningzheng Donga,b,1, and Qingyu Wua,e,1 aCyrus Tang Hematology Center, Ministry of Education Engineering Center of Hematological Diseases, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Soochow University, 215123 Suzhou, China; bMinistry of Health Key Laboratory of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 215006 Suzhou, China; cDepartment of Orthopedics, The Second Affiliated Hospital of Soochow University, 215004 Suzhou, China; dCambridge-Soochow University Genomic Resource Center, Soochow University, 215123 Suzhou, China; and eCardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 Edited by R. Michael Roberts, University of Missouri, Columbia, MO, and approved June 25, 2020 (received for review February 29, 2020) Spiral artery remodeling is an important physiological process in the In the heart, natriuretic peptide expression is controlled by pregnant uterus which increases blood flow to the fetus. Impaired GATA-4, a zinc finger transcription factor (21, 22). A similar spiral artery remodeling contributes to preeclampsia, a major disease GATA-4–dependent mechanism is critical for cardiac corin ex- in pregnancy. Corin, a transmembrane serine protease, is up- pression. We have shown that human and mouse corin gene pro- regulated in the pregnant uterus to promote spiral artery remodeling. moters contain a conserved sequence that is essential for GATA-4 To date, the mechanism underlying uterine corin up-regulation re- binding and corin expression in cardiomyocytes (23).
    [Show full text]